BLSI Boston Life Sciences (MM)

HOPKINTON, Mass., March 7 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI) today announced that Ken Rice, Executive Vice President and Chief Financial Officer of Boston Life Sciences, Inc., will be presenting a Company update at the Sachs Associates 6th Annual North America Forum for Investing & Partnering in Biotech on Monday, March 12 at 10:55am EDT. The conference is being held on March 12 at the Fairmont Copley Plaza in Boston, MA. The Boston Life Sciences presentation will be available by webcast. Access to the webcast will be available within the Investor Relations section of the Boston Life Sciences website at http://www.bostonlifesciences.com/. About Boston Life Sciences, Inc. Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinson's Disease (PD) and Phase II clinical trials for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). Cethrin(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, has reported positive interim results in a North American Phase I/IIa clinical trial. The company's research and pre- clinical CNS programs include Inosine for the treatment of spinal cord injury and stroke, a DAT blocker for the treatment of Parkinson's disease, and a second generation technetium-based molecular imaging agent for PD and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital Boston. Contact: Meredith Patin -- 508-497-2360 ext 239 Boston Life Sciences, Inc. DATASOURCE: Boston Life Sciences, Inc. CONTACT: Meredith Patin of Boston Life Sciences, Inc., +1-508-497-2360, ext. 239, or Web site: http://www.bostonlifesciences.com/

Copyright